tradingkey.logo
tradingkey.logo
Search

GSK seeks FDA nod for expanded use of RSV vaccine in adults

ReutersJul 14, 2025 6:11 AM
facebooktwitterlinkedin
View all comments0

- British drugmaker GSK GSK.L said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults under the age of 50 at a higher risk of the disease.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI